January 8, 2025

WuXi Global Forum 2025

Date and time

January 14, 2025 ~ January 14, 2025

1:30 PM-6:00 PM PST

Location

San Francisco

Dear colleagues and friends,

For 13 years, WuXi Global Forum has been our way of celebrating the spirit of collaboration — each year uniting thousands of global leaders and entrepreneurs dedicated to advancing breakthroughs for patients. Continuing this spirit, WuXi Global Forum 2025 will take place in San Francisco on January 14, 2025 during the week of the 2025 J.P. Morgan Healthcare Conference, and remains complimentary as in previous years.

This year’s Opening Plenary will once again provide critical perspectives on the “State of Innovation”, and the more than 100 Executive Roundtables hosted by C-suite leaders will brings a unique blend of partnering focus, expert insights, and dynamic energy – fostering personalized and in-depth conversations among all participants. Together we honor the essence of our industry: a shared journey of knowledge, collaboration and advancement.

EVENTS

WuXi Executive Breakfast in Basel: The Most Important Innovation in Drug R&D May Be How the Industry Works Together

Reflections from the WuXi Executive Breakfast at Swiss Biotech Day

May 11, 2026

READ MORE

FEATURED

Reflection on the First Approved PROTAC and the Future of Small Molecule Drugs: A Conversation with Prof. Craig Crews, Yale University

In May 2026, the FDA approved the first PROTAC therapy, marking the arrival of an entirely new class of medicines built on a once-radical idea: instead of merely inhibiting disease-causing proteins, drugs could be designed to eliminate them altogether. At the center of that story is Prof. Craig Crews, whose laboratory at Yale University helped pioneer the PROTAC (PROteolysis TArgeting Chimera) approach more than two decades ago.

June 8, 2026

Many years later, staring at five kilograms of pale drug powder sealed inside a plastic bag, Craig Crews remembered that afternoon in the late 1990s, when almost nobody stopped to see his poster.

June 8, 2026

Across complex therapeutic areas, innovators are applying an expanding range of new modalities, from antibody-drug conjugates (ADCs) and bispecific antibodies to peptides, oligonucleotides, and other advanced formats. Yet as the therapeutic toolbox expands, one principle remains central: modality should follow biology...

May 28, 2026

READ MORE